Identification of biomarkers for the diagnosis in colorectal polyps and metabolic dysfunction-associated steatohepatitis (MASH) by bioinformatics analysis and machine learning

被引:1
|
作者
Geng, Ying [1 ]
Li, Yifang [1 ]
Liu, Ge [1 ]
Jiao, Jian [1 ]
机构
[1] Jilin Univ, China Japan Union Hosp, Dept Gastroenterol & Hepatol, Changchun 130033, Peoples R China
来源
SCIENTIFIC REPORTS | 2024年 / 14卷 / 01期
关键词
Colorectal polyps; Metabolic dysfunction associated steatohepatitis (MASH); Bioinformatics analysis; Machine learning; Bile acids; FATTY LIVER-DISEASE; COLON-CANCER; CELLS; EXPRESSION; MIGRATION; PATHWAY; S100P; ACTIVATION; INHIBITOR; RECEPTORS;
D O I
10.1038/s41598-024-81120-8
中图分类号
O [数理科学和化学]; P [天文学、地球科学]; Q [生物科学]; N [自然科学总论];
学科分类号
07 ; 0710 ; 09 ;
摘要
Colorectal polyps are precursors of colorectal cancer. Metabolic dysfunction associated steatohepatitis (MASH) is one of metabolic dysfunction associated fatty liver disease (MAFLD) phenotypic manifestations. Much evidence has suggested an association between MASH and polyps. This study investigated the biomarkers of MASH and colorectal polyps, and the prediction of targeted drugs using an integrated bioinformatics analysis method. Differentially expressed genes (DEGs) analysis and weighted gene co-expression network analysis (WGCNA) were performed on GSE89632 and GSE41258 datasets, 49 shared genes revealed after intersection. The Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) enrichment analyses depicted they were mainly enriched in apoptosis, proliferation and infection pathways. Machine learning algorithms identified S100P, FOXO1, and LPAR1 were biomarkers for colorectal polyps and MASH, ROC curve and violin plot showed ideal AUC and stable expression patterns in both the discovery and validation sets. GSEA analysis showed significant enrichment of bile acid and fatty acid pathways when grouped by the expression levels of the three candidate biomarkers. Immune infiltration analysis showed a significant infiltration of M0 macrophages and Treg cells in the colorectal polyps group. A total of 9 small molecule compounds were considered as potential chemoprevention agents in MASH and colorectal polyps by using the CMap website. Using integrated bioinformatics analysis, the molecular mechanism between MASH and colorectal polyps has been further explored.
引用
收藏
页数:17
相关论文
共 50 条
  • [41] Effects of Metabolic Dysfunction-Associated Steatohepatitis in Alertness, Associative Learning, and Astrocyte Density
    Higarza, Sara G.
    De Anton-Cosio, Marina
    Zorzo, Candela
    Arias, Jorge L.
    Arias, Natalia
    BRAIN AND BEHAVIOR, 2025, 15 (01):
  • [42] EFFICACY AND ADVERSE EVENTS OF RESMETIROM 80 MG IN METABOLIC DYSFUNCTION-ASSOCIATED STEATOHEPATITIS (MASH): A SYSTEMATIC REVIEW AND META-ANALYSIS
    Nekkanti, Ankita
    Vohra, Ishaan
    Gopakumar, Harishankar
    Dhillon, Sonu
    Sharma, Neil
    Puli, Srinivas
    HEPATOLOGY, 2024, 80
  • [43] COST-COMPARISON ANALYSIS OF NON-INVASIVE TESTING STRATEGIES FOR METABOLIC DYSFUNCTION-ASSOCIATED STEATOHEPATITIS (MASH) IN VETERAN POPULATION
    Boltyenkov, A.
    Chang, S.
    Chalfin, D. B.
    Sangha, K.
    Cheung, R.
    VALUE IN HEALTH, 2024, 27 (06) : S135 - S135
  • [44] METABOLOMIC AND LIPIDOMIC ANALYSIS OF PATIENTS WITH PRESUMED METABOLIC DYSFUNCTION-ASSOCIATED STEATOHEPATITIS (MASH) TREATED WITH THE SELECTIVE GLUCOCORTICOID RECEPTOR MODULATOR MIRICORILANT
    Kowdley, Kris
    Noureddin, Mazen
    Parks, Elizabeth
    Botbyl, Jeffrey
    Monibas, Rafael Mayoral
    Wadekar, Subhagya
    Espinueva, Aprille
    Juneja, Kavita
    Schwab, Andrew
    Alkhouri, Naim
    HEPATOLOGY, 2024, 80
  • [45] New advances in novel pharmacotherapeutic candidates for the treatment of metabolic dysfunction-associated steatohepatitis (MASH) between 2022 and 2024
    Wong, Shu Wei
    Yang, Yong-yu
    Chen, Hui
    Xie, Li
    Shen, Xi-zhong
    Zhang, Ning-ping
    Wu, Jian
    ACTA PHARMACOLOGICA SINICA, 2025,
  • [46] Non-invasive assessment of liver inflammation in metabolic dysfunction-associated steatohepatitis (MASH) using MRI cytometry
    Jiang, Xiaoyu
    Izzy, Manhal
    Washington, Kay
    Gore, John
    Xu, Junzhong
    JOURNAL OF HEPATOLOGY, 2024, 80 : S595 - S595
  • [47] METABOLISM AND THERAPEUTIC EFFECTS OF N-ACYL AMINO ACIDS IN METABOLIC DYSFUNCTION-ASSOCIATED STEATOHEPATITIS (MASH) AND ATHEROSCLEROSIS
    Anand, Sumit Kumar
    Das, Sandeep
    Lee, Jennifer
    Richard, Koral
    McKinney, Peyton
    Rohilla, Sumati
    Pandey, Nilesh
    Kumar, Dhananjay
    Pearson-Gallion, Brenna
    Wang, Lu
    Finney, Alexandra
    Zhang, Jifeng
    Sun, Duxin
    Liu, Wanqing
    Chen, Eugene
    Orr, Wayne
    Dhanesha, Nirav
    Yurdagul, Arif
    Rom, Oren
    HEPATOLOGY, 2024, 80
  • [48] DEGREE OF METABOLIC DYSFUNCTION IS LINKED TO STEATOHEPATITIS (MASH), FIBROSIS, AND HIGHER CARDIOVASCULAR RISK IN PATIENTS WITH METABOLIC DYSFUNCTION-ASSOCIATED STEATOTIC LIVER DISEASE (MASLD)
    Kim, David
    Abboud, Yazan
    Ismail, Mohamed
    Goyal, Ritik Mahaveer
    Pyrsopoulos, Nikolaos
    Kim, Hyunseok
    Hajifathalian, Kaveh
    Al-Khazraji, Ahmed
    HEPATOLOGY, 2024, 80 : S441 - S442
  • [49] Exercise training improves serum biomarkers of liver fibroinflammation in patients with metabolic dysfunction-associated steatohepatitis
    Harris, Sara J.
    Smith, Nataliya
    Hummer, Breianna
    Schreibman, Ian R.
    Faust, Alison J.
    Geyer, Nathaniel R.
    Chinchilli, Vernon M.
    Sciamanna, Chris
    Loomba, Rohit
    Stine, Jonathan G.
    LIVER INTERNATIONAL, 2024, 44 (02) : 532 - 540
  • [50] Untargeted lipidomic analysis of metabolic dysfunction-associated steatohepatitis in women with morbid obesity
    Bertran, Laia
    Capellades, Jordi
    Abello, Sonia
    Richart, Cristobal
    PLOS ONE, 2025, 20 (03):